{
  "long_title" : "A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas",
  "nct_id" : "NCT001",
  "phase" : "I",
  "short_title" : "A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral Murine Double Minute 2 (MDM2) Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas",
  "status" : "Active",
  "treatment_list" : {
    "step" : [ {
      "arm" : [ {
        "arm_description" : "DS-3032: Dose Expansion",
        "arm_eligibility" : "Part 2 (Additional Inclusion Criteria for Solid Tumor/Lymphoma Dose Expansion) 1. Has a histologically or cytologically documented advanced melanoma or DLBCL with measurable disease that is refractory to standard treatment or for which no standard treatment is available. \n\nExclusion Criteria:\nPart 2 (Additional Inclusion Criteria for Solid Tumor/Lymphoma Dose Expansion) 1. Has a tumor which contains a nonsynonymous mutation, insertion, or deletion in the TP53 gene determined previously or at screening. \n",
        "arm_info" : "DS-3032b will be administered as an oral capsule. It will be supplied in 5 mg, 20 mg, 80 mg, and 200 mg capsules individually packaged in desiccant-embedded aluminum blisters.",
        "match" : [ {
          "and" : [ {
            "genomic" : {
              "annotated_variant" : "Wildtype",
              "hugo_symbol" : "TP53"
            }
          }, {
            "or" : [ {
              "clinical" : {
                "age_numerical" : ">=18",
                "oncotree_primary_diagnosis" : "Melanoma"
              }
            }, {
              "clinical" : {
                "age_numerical" : ">=18",
                "oncotree_primary_diagnosis" : "Diffuse Large B-Cell Lymphoma, NOS"
              }
            } ]
          } ]
        } ]
      } ]
    } ]
  }
}